Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Champions Biotechnology has signed agreements with Centocor R&D for the preclinical evaluation of certain therapeutic agents in Centocor's clinical development pipeline. As part of the agreements, Centocor will utilize Champions Biotechnology's Biomerk Tumorgrafts to evaluate promising antibodies.
Subscribe to our email newsletter
Doug Burkett, president of Champions Biotechnology, said: “Studies suggest that our Biomerk Tumorgrafts closely reflect human cancer biology and their response to drugs is more predictive of clinical outcomes in cancer patients.
“A growing number of pharmaceutical and biotechnology companies are beginning to recognize the predictive potential of Biomerk Tumorgrafts. Centocor has an impressive track record in the research, development, and commercialization of human therapeutic agents and we are delighted to enter into these agreements with the company.”